Objective. Systemic lupus erythematosus (SLE) is more prevalent and results in more severe outcomes among blacks, Asians, and Hispanics than among whites. Cardiovascular disease (CVD) is the leading cause of death among SLE patients. We undertook this study to examine racial/ethnic variations in risk of CVD events among SLE patients.
stroke, and heart failure among SLE patients compared to age-matched controls, particularly among women age ,45 years (9, 10, (12) (13) (14) (15) . SLE itself remains an independent CVD risk factor after controlling for known CVD risk factors (16) . In a population-based study of .90,000 US hospitalizations for SLE, blacks were younger than whites at admission for CVD, suggesting important disparities (17) . Furthermore, CVD morbidity and mortality rates may be especially high among lupus nephritis patients, who have high rates of hypertension, hyperlipidemia, and use of high-dose glucocorticoids (18) (19) (20) . However, relatively little is known about variations in the rates of CVD by race/ethnicity among SLE and lupus nephritis patients.
To address these significant knowledge gaps, we examined rates and relative risks of CVD events overall and by race/ethnicity among SLE and lupus nephritis patients in a multiracial cohort of 65,788 SLE patients. We hypothesized that CVD event rates and relative risks would be elevated among black and American Indian/Alaska Native SLE patients compared to white SLE patients.
PATIENTS AND METHODS
Study population. Medicaid is the US health insurance program for individuals with low income and limited resources, providing coverage for medical expenses and prescription drugs. We analyzed data from the Medicaid Analytic eXtract (MAX), an administrative database containing all billing claims for Medicaid patients from the 29 most populated US states (21) . We included adults ages $18 years to 65 years between January 1, 2000 and December 31, 2010. We excluded patients .65 years of age, as .90% are dually enrolled in Medicare, and thus, not all claims are captured in Medicaid.
We identified prevalent SLE as previously described ($3 International Classification of Diseases, Ninth Revision [ICD-9] codes for SLE [710.0] , from hospital discharge diagnoses or physician visit claims, $30 days apart) (5) . Among SLE patients, we identified those with lupus nephritis ($2 additional ICD-9 claims for nephritis, proteinuria, and/or renal failure on or after the index date, $30 days apart) (22) . We restricted analyses to patients with $12 months of continuous Medicaid enrollment prior to the index date for collection of baseline covariates. The index date was defined as the date of the $3rd SLE billing code preceded by $12 months of continuous Medicaid enrollment.
Definition of race/ethnicity. Race/ethnicity in the MAX database is based on self-report, in mutually exclusive categories of white, black or African American, American Indian/ Alaska Native, Hispanic or Latino, and Asian (including Native Hawaiian or other Pacific Islander) (23) . Individuals whose race/ethnicity information was missing or nonclassifiable (e.g., "other/unknown" or "more than one race" categories) were excluded.
Outcome measures. The primary outcome measure was the first CVD event after the index date, defined as a composite measure of the time to either a first acute MI or stroke (24) (25) (26) (27) Outcomes in the primary analysis were based on primary and secondary hospital discharge diagnosis codes, accounting for the possibility that SLE was billed as the primary diagnosis and CVD event as a secondary diagnosis. Patients were followed up from the day after the index date to first MI or stroke, death, loss to follow-up (no further medical claims in the absence of documented death), Medicaid disenrollment, or end of follow-up period. Deaths were reported directly to Medicaid and were also obtained from the National Death Index. Cause of death was not available.
Covariates. Baseline data from 12 months prior to the index date included demographic, SLE-related, and CVDrelated covariates. Demographic variables were age, sex, and US Census-based region of residence (determined by zip code and categorized as Northeast, Midwest, South, or West). For area-based socioeconomic status (SES), we used a validated composite index of 7 zip code SES indicators from 2000 US Census data (28). We divided area-level SES data into quartiles (5) .
To characterize SLE-related comorbidities, we used the "SLE risk adjustment index," a validated measure for prediction of in-hospital mortality among SLE patients that uses comorbidities specific for SLE (29) . We used the median score to divide patients into categories of high or low risk of SLE. We categorized mean baseline glucocorticoid use (0 to 5 mg/day, .5 to 15 mg/day, and .15 mg/day) for interpretability. We also evaluated baseline warfarin use (ever/ never), which may serve as a proxy for antiphospholipid syndrome (APS). We evaluated baseline CVD comorbidities using validated ICD-9 and/or Current Procedural Terminology and/or Diagnosis-Related Group codes for stroke, hypertension, hyperlipidemia, diabetes mellitus, smoking, obesity, acute MI, old MI, angina, percutaneous coronary intervention (PCI), coronary atherosclerosis, and coronary artery bypass graft (CABG) (30) (31) (32) (33) Statistical analysis. We calculated unadjusted CVD incidence rates (IRs) and incidence rate ratios (IRRs) overall and by race/ethnicity for SLE per 1,000 person-years, with 95% confidence intervals (95% CIs). To investigate contributions of different sets of factors, we fit 3 multivariable Cox subdistribution proportional hazards models, calculating cause-specific risk while accounting for the competing risk of death (34) . In each of our models (A through C), while accounting for death as a competing risk, we estimated hazard ratios (HRs) for each outcome by race/ethnicity among SLE and lupus nephritis patients. Model A included age (continuous) and sex. Model B added sociodemographic variables and SLE-related risk factors (SLE risk adjustment index, glucocorticoid use, and lupus nephritis) to model A. Finally, model C added cardiac-specific risk comorbidities to model B, including history of hypertension, smoking, hyperlipidemia, diabetes mellitus, and obesity. We tested the proportional hazards assumption, using Kaplan-Meier curves as well as timevarying covariates by race/ethnicity, for the variables of interest, and we observed no significant deviations in our models. 1824 BARBHAIYA ET AL We performed 4 sensitivity analyses. First, we included only primary discharge diagnosis codes for all outcomes. Second, we excluded patients with a history of CVD (PCI, CABG, coronary atherosclerosis, acute MI, heart failure, stroke, or "past MI") at baseline. Third, we separately examined risks among Hispanics who self-reported $1 race and among those who reported only Hispanic ethnicity. Finally, we examined the effect of additional adjustment for baseline warfarin use on our final models for CVD, MI, and stroke.
All statistical analyses were conducted using SAS software, version 9.3 (SAS Institute). Data were obtained from Centers for Medicare and Medicaid Services (CMS) through an approved Data Use Agreement and are presented in accordance with CMS policies (cell sizes of ,11 individuals have been suppressed). The Partners Institutional Review Board approved all aspects of this study.
RESULTS
We included 65,788 patients with prevalent SLE from 2000 to 2010. Their baseline characteristics are shown in Table 1 . Their mean 6 SD age was 40.8 6 12.1 years; 93.1% were women, and the largest proportion resided in the South (40%). The racial/ethnic breakdown was 42% black, 38% white, 16% Hispanic, 3% Asian, and 1% American Indian/Alaska Native. Black SLE patients had a higher prevalence of hypertension and heart failure than all other races/ethnicities. Compared to whites, Hispanics had lower baseline rates of angina, coronary atherosclerosis, stroke, MI, smoking, heart failure, obesity, CABG, and PCI, but similar rates of diabetes mellitus and hypertension. Asians had the lowest prevalence of coronary atherosclerosis, diabetes mellitus, hypertension, obesity, stroke, and smoking, but had the highest proportion of lupus nephritis and rates of mean glucocorticoid use .5 mg/day, compared to all other races/ethnicities. The prevalence of diabetes mellitus, obesity, and MI at the index date was highest among American Indians/Alaska Natives. The SLE risk After multivariable adjustment for sociodemographic factors as well as SLE-and CVD-specific factors, and accounting for the competing risk of death, racial/ethnic variation in CVD event risks among black SLE patients persisted. The multivariable HRs from models A through C for the primary outcome of CVD, in addition to CVD components of MI and stroke separately, are shown in Table 3 Lupus nephritis subgroup. Patients with lupus nephritis (n 5 13,966 [21.2%]) were younger (mean 6 SD age 37.6 6 12.5 years) and had a higher prevalence of many baseline CVD risk factors, including angina, coronary atherosclerosis, diabetes mellitus, hyperlipidemia, hypertension, stroke, heart failure, MI, PCI, and CABG. Lupus nephritis patients also had increased use of warfarin and higher mean daily glucocorticoid doses compared to the overall SLE group. Furthermore, the SLE risk adjustment index was nearly 2-fold higher among lupus nephritis patients than that among all patients with prevalent SLE (3.83 6 3.29 versus 1.64 6 2.59). Among patients with lupus nephritis, We also evaluated the association of warfarin use with risk of CVD. At baseline, the overall prevalence of warfarin use was 6.9% in SLE, with similar rates by race/ethnicity. Additional adjustment for warfarin use yielded unchanged results compared to our final model (model C) for the outcomes of CVD, MI, or stroke among SLE patients by race/ethnicity (data not shown).
DISCUSSION
Within a cohort of .65,000 racially, ethnically, and geographically diverse SLE patients from the 29 most populated US states, we observed marked racial/ ethnic variations in CVD event rates and relative risks. Blacks with SLE had a 14% increased risk of CVD. We also found the risk of MI reduced among Hispanics by 39% and among Asians by 43% compared to whites. Risk of stroke was increased by 31% among blacks and by 22% among Hispanics compared to whites. Sequential adjustment for sociodemographic factors and SLEand CVD-specific comorbidities attenuated the increased risk of stroke among blacks, suggesting that these factors may explain some of this excess risk. In a sensitivity analysis excluding those with prior CVD events at baseline, we observed similar racial and ethnic disparities in outcomes in Hispanics, Asians, and blacks compared to whites, suggesting that a history of CVD does not alter the subsequent risk of a CVD event.
The demonstration of substantially reduced risk of MI in Hispanic and Asian SLE patients compared to white SLE patients is novel. SLE has been reported to be more prevalent and more severe and to result in more end-organ damage in Hispanic and Asian patients compared to white patients (35, 36) . However, we have previously reported 52% and 41% lower adjusted allcause mortality risk among Hispanic and Asian patients, respectively, compared to white patients within this Medicaid SLE cohort (8) . The current results suggest a similar "Hispanic and Asian paradox" for reduced MI risk, possibly contributing to the lower mortality risk. Hispanics in the general US population have a high prevalence of many CVD risk factors, including hypertension, diabetes mellitus, physical inactivity, obesity, and metabolic syndrome (37) . Nonetheless, paradoxically lower rates of coronary death, vascular death, and total mortality have been demonstrated among Hispanics compared to non-Hispanics in the general population (37, 38) .
CVD risk is less well characterized among Asians in the US. National prevalence rates for coronary heart disease among Asian adults are lower than those among non-Hispanic whites (2.9% versus 6.5%) (39) . Although Asians have been shown to have similar rates of classic CVD risk factors compared to whites overall, this risk can vary substantially by subgroup (40) . Furthermore, studies examining CVD risk among Asians versus whites have typically demonstrated no association, which is largely thought to be due to varied risks among Asian subgroups (41) .
One possible explanation for the observed reduced risk of MI among Hispanics and Asians includes incomplete ascertainment of MI events, as immigrants may return to their countries of origin during illness or at end of life, and thus are not captured in claims data, potentially leading to underascertainment of adverse outcomes (42) . However, we previously investigated this possibility and did not demonstrate the existence of differential loss to follow-up among Hispanics or Asians in our SLE Medicaid cohort (8) . Additionally, immigrants who do not "acculturate" may follow a healthier lifestyle than US whites, with healthier diets and less smoking (43) . Hispanics and Asians in our cohort were slightly younger and had a lower SLE risk adjustment index (indicator of SLE severity) than white or black patients, but adjustment for these and other CVD risk factors did not influence the reduced risk of MI observed. Despite having the highest proportion of patients with lupus nephritis and the greatest use of moderate-to-high-dose glucocorticoids, Asians still had reduced risk of MI in age and sex-adjusted models. Additionally, although Asians and Hispanics had fewer CVD risk factors than whites, adjustment for these factors did not account for the reduced risk. Claims data do not contain granular data such as smoking duration/ intensity, systolic blood pressure, cholesterol levels, or hemoglobin A 1c values, all of which may be potential contributors to CVD risk. The observed "paradox" may be the result of complex interactions between environmental, cultural, socioeconomic, psychosocial, genetic, and other clinical factors. Further studies, possibly with more clinical and sociodemographic data, are needed to delve deeper into this question.
Our finding of elevated stroke risk among black and Hispanic SLE patients is consistent with the known increased stroke burden among blacks and Hispanics in the US general population (44) . Although blacks with SLE have been shown to have increased risks of CVD events (defined as a composite of MI, angina, and/or cardiac procedures) compared to white SLE patients (17) , in the current study blacks did not have an elevated risk of MI, but did have a 31% increased risk of stroke compared to whites. The reasons for these discrepant findings are not clear. In our cohort, black patients had higher SLE risk indices and more hypertension, and a higher proportion of them had lupus nephritis. However, Hispanics and whites had similar rates of hypertension, but a higher proportion of Hispanics had lupus nephritis. Additionally, stroke risks remained unchanged despite adjustment for warfarin use; however, given that prevalence of warfarin use was lower than reported rates of APS in SLE (45), warfarin may not be an accurate APS surrogate in this population. Results of laboratory testing for antiphospholipid antibodies and effective anticoagulation would be more informative but are unavailable in claims. Thus, while it is impossible to determine the biologic basis of these differences from an administrative cohort such as MAX, possible explanations include residual effects of hypertension or racial differences in the nature and severity of SLE that are not fully captured by the covariates included in the adjusted models.
A main strength of this study is the use of more than a decade of data on .43,000 SLE patients. Data concerning sociodemographic factors and SLE-and CVD-specific comorbidities were available in administrative claims. We fit several models to adjust for potential confounders and mediators that might contribute to increased CVD risk among SLE patients, while accounting for the competing risk of death. As diagnostic claims for CVD events may cause an underestimation of event rates (46), we used primary and secondary codes in our primary analysis. We also performed sensitivity analyses, which demonstrated even stronger associations of race/ ethnicity with CVD risk after exclusion of participants with a history of CVD at baseline. Furthermore, in an additional sensitivity analysis, we demonstrated that CVD risk among Hispanics self-reporting other races was similar to that among Hispanics without additional race data, confirming the robustness of our main results. Additionally, we applied the previously validated SLE risk adjustment index to the Medicaid population to capture SLE severity and SLE-related comorbidities. Finally, our estimates of SLE prevalence among black women are similar to those published for Centers for Disease Control and Prevention-funded epidemiology projects in Michigan and Georgia, providing external validation of our methods (8, 47, 48) .
There are limitations inherent in using Medicaid data for the study of SLE outcomes by race/ethnicity, including use of an administrative case definition to identify prevalent SLE and potential misclassification of race/ethnicity, in addition to the inability to examine risks among those .65 years of age given dual enrollment in Medicare, which was not part of this data set (8) . By requiring 12 months of continuous enrollment prior to the index date, we reduced the study sample size somewhat. Although the sample size was adequate to detect associations in the SLE cohort, the analysis may have been underpowered to detect significant associations in the lupus nephritis subgroup. Body mass index, physical exercise, diet, and lifestyle behaviorswhich are related to CVD risk-are not adequately captured in administrative data. Moreover, the self-reported US "Hispanic" and "Asian" populations are heterogeneous ethnic groups and genetically admixed populations, and the current data do not include country of origin, genetic ancestry information, or sociocultural experience.
Furthermore, although Medicaid patients may be more ill than privately insured patients in the US, we do not suspect that we included a disproportionate number of patients with severe SLE. Although we cannot directly measure SLE-related damage or activity in claims data, patients with lupus nephritis, who typically have more aggressive SLE, comprised 21% of our SLE cohort. The SLE risk adjustment index, a proxy for SLE severity, was low for SLE overall and by race/ethnicity. Use of a cohort of patients with prevalent SLE also limited the ability to investigate the effect of SLE duration or cumulative exposure to glucocorticoids. Additionally, we were not able to account for CVD events without hospitalization. Finally, as Medicaid provides health care coverage for low-income US populations, our results may not be generalizable to groups with higher SES; however, they certainly pertain to a large proportion of the US population. Based on our data, ;55,000 adult SLE patients were enrolled in 2010; thus, among an estimated 161,000 to 322,000 total adult SLE patients in the US (49) , Medicaid in 2010 covered ;17-35% of the US SLE patient population. (The Medicaid program in 2010 included ;22% of the US population (50).)
In conclusion, marked racial/ethnic variation in CVD event rates and risks was uncovered within a large cohort of racially/ethnically diverse, low-income SLE patients at high risk of adverse outcomes. Compared to white SLE patients, black and Hispanic SLE patients had an elevated risk of stroke, while the risk of MI was reduced among Hispanic and Asian SLE patients despite adjustment for sociodemographic factors and SLE-and CVD-specific comorbidities, in addition to accounting for the competing risk of death. Future research on SLE among racial/ethnic groups should consider the role of diversity in genetic factors, biomarkers, lifestyle and physical activity, other thrombotic risk factors, and socioeconomics among various subpopulations and should evaluate potential gene-environment interactions in relation to CVD risk. Improved understanding of race/ethnicity-specific CVD rates and risks could allow improved prevention strategies, including risk stratification and earlier diagnosis and management of CVD events.
